NasdaqGS:VYGRBiotechs
Voyager Therapeutics (VYGR) Q4 Loss Of US$27 Million Reinforces Bearish Profitability Concerns
Voyager Therapeutics (VYGR) has released its FY 2025 numbers with Q4 revenue of US$15.3 million and a basic EPS loss of US$0.47, alongside a trailing twelve month revenue figure of US$40.4 million and basic EPS of US$2.04 loss. The company has seen quarterly revenue range from US$5.2 million to US$15.3 million over FY 2025 while basic EPS losses moved between US$0.47 and US$0.57, all against a backdrop of TTM net income of US$119.7 million loss and revenue growth running at about 7.8% per...